Clinical trials · New York, NY
Parkinson’s disease clinical trials in New York
We’re tracking 35 recruiting parkinson’s disease studies with a site in or near New York — including Early Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06976268RecruitingPhase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
New York, New YorkAges 40–80 - NCT07330258Recruiting
Observing Parkinson's over time in people still having movement symptoms
This study follows people with Parkinson's disease who still have movement symptoms despite taking medication. It aims to understand how the disease changes over time, which could help improve future treatments.
New York, New YorkAges 45–75 - NCT07174310RecruitingPhase 3
Prasinezumab for early Parkinson's disease
This study tests a new medication called prasinezumab, given through a vein (IV), to see if it can slow the progression of early-stage Parkinson's disease. It is for people who are on only one Parkinson's medication and have not yet developed motor complications.
New York, New YorkAges 50–85 - NCT07005180RecruitingPhase 2
Carbon monoxide gas for Parkinson's disease
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
New York, New YorkAges 40–80 - NCT06285643RecruitingPhase 2
Gene therapy for moderate Parkinson's disease
This trial tests a gene therapy (AAV2-GDNF) to see if it can slow or improve symptoms of Parkinson's disease. It is for people who have had moderate Parkinson's for 4 to 10 years and still respond to levodopa therapy.
New York, New YorkAges 45–75 - NCT07567794Recruiting
Gut-Brain Connection Study in Parkinson's Disease
This research examines how the gut and brain are connected in Parkinson's disease and aims to better understand the disease. You'd participate in visits and tests over three years, including some involving your digestive system.
New York, New YorkAges 21–80 - NCT04477785Recruiting
Study to track Parkinson’s signs using imaging, spinal fluid, and genes
This study is building a large, detailed group of people—some with Parkinson’s and some at higher risk—to understand early changes over time. It uses brain imaging (DaTscan SPECT), sometimes spinal fluid tests (lumbar puncture), and genetic information to help researchers better measure disease and develop future treatments.
New York, New YorkAges 30 years+ - NCT05539196Recruiting
Registry for Exablate treatment in Parkinson’s with medication problems
This trial is a real-world registry that follows people with Parkinson’s who are planning to get an Exablate 4000 procedure (a focused ultrasound treatment) for one-sided symptoms that are difficult to control with medication. It mainly checks outcomes and safety over time, helping doctors understand how well this treatment works in everyday care.
New York, New YorkAges 30–99 - NCT05347407Recruiting
Gut nerve cell biomarkers study for Parkinson’s risk
This trial studies nerve cell “biomarkers” from the gut to learn whether they can help detect Parkinson’s disease (or related conditions) earlier. You may be asked to undergo a colonoscopy to collect gut tissue for testing.
New York, New YorkAges 45–75 - NCT04994015RecruitingTeam says not enrolling
Genetic registry for people with Parkinson’s
This study builds a genetics “registry” of people diagnosed with Parkinson’s disease who agree to genetic testing. Your information may help researchers understand why Parkinson’s happens and improve future treatments.
New York, New YorkAges 18 years+ - NCT05536388Recruiting
Study of a new drug for GBA-related Parkinson’s
This study is looking for ways to find new drugs that may help people with Parkinson’s caused by changes in the GBA gene. It may also include people with Gaucher disease and healthy volunteers, using blood and possibly skin samples.
New York, New YorkAges 18 years+ - NCT06540989RecruitingEarly Phase 1
Speech therapy with computer feedback for Parkinson's
This study tests a new speech therapy approach for people with Parkinson's disease who have mild to moderate speech problems. It uses a computer program that listens to your speech and helps you practice speaking more clearly.
New York, New YorkAges 50–80 - NCT04991831Recruiting
Registry study for Exablate thalamotomy in tremor-dominant Parkinson’s
This study follows people who are getting an Exablate procedure to treat medication-resistant, tremor-dominant Parkinson’s. It aims to track safety and outcomes in real-world care after the treatment is approved.
New York, New YorkAges 30–99 - NCT05700825RecruitingPhase 2
Rehab training to improve swallow safety in Parkinson’s
This trial tests a rehabilitation approach aimed at improving airway protection during swallowing in people with Parkinson’s disease. It may help reduce the risk of food or liquid going down the wrong way by improving swallow safety.
New York, New YorkAges 50–90 - NCT05897957Enrolling by invitation
Follow-up study for people who received BRT-DA01
This study is for people with Parkinson’s disease who previously took part in an earlier BRT-DA01 trial and finished it (or stopped it). It mainly checks how participants do over time after that earlier treatment.
New York, New YorkAges 50–78 - NCT06944522RecruitingPhase 3
Cell therapy for Parkinson's symptoms
This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.
New York, New YorkAges 45–75 - NCT07752355Recruiting
Parkinson's subtypes and causes in young onset disease
This study looks at different types of Parkinson's disease, especially in people diagnosed before age 50. It involves a small skin biopsy to help understand what causes the disease.
New York, New YorkAges 18 years+ - NCT04239079Recruiting
Study of immune-related changes in Parkinson’s and Alzheimer’s
This study looks for “autoimmune-like” (immune-system) features in brain-related diseases such as Parkinson’s and Alzheimer’s, using genetic testing and other assessments. Results may help researchers understand what drives these conditions and who might be more likely to have immune-related changes.
New York, New YorkAges 55–90 - NCT07284784RecruitingPhase 2/Phase 3
Buntanetap for Parkinson's disease study
This trial tests an investigational drug called buntanetap in people with Parkinson's disease. It aims to see if the drug can improve symptoms. There are two groups: those who've taken buntanetap before (Cohort 1) and those with a deep brain stimulator (DBS) implant for at least a year (Cohort 2).
New York, New YorkAges 40–85 - NCT07207122Recruiting
Focused ultrasound for Parkinson's cognitive symptoms
This trial tests whether a non-invasive ultrasound treatment, called transcranial focused ultrasound stimulation (tFUS), can improve movement and thinking in people with Parkinson's disease. It may be an option for those whose symptoms are not well controlled by medication alone.
New York, New YorkAges 22–80 - NCT05779475Enrolling by invitation
Study of people with moderate Parkinson’s disease
This is an observational study, meaning it doesn’t test a new drug—researchers mainly follow people to better understand moderate Parkinson’s disease and who may be good candidates for future cell therapy. If you have moderate symptoms that aren’t well controlled with tablets, this study may help inform better future treatments.
New York, New YorkAges 50–68 - NCT06753331RecruitingPhase 1/Phase 2
Study of DSP-1083 for Parkinson's disease
This trial tests a new treatment called DSP-1083 for people with Parkinson's disease whose symptoms are not well controlled with standard medications. The study will check if it is safe and if it helps improve movement and daily function.
New York, New YorkAges 40–72 - NCT06680830RecruitingPhase 2
Testing NEU-411 for early Parkinson's with LRRK2 gene change
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
New York, New YorkAges 40–80 - NCT07102342RecruitingPhase 1/Phase 2
Cell therapy for Parkinson's disease
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
New York, New YorkAges 30–75
Hear when a new Parkinson’s disease trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Parkinson’s disease trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting parkinson’s disease studies listed above.
- Weill Cornell Medicine · 8 studies
- Columbia University Irving Medical Center · 7 studies
- NYU Langone Health · 3 studies
- Mount Sinai Health System · 2 studies
- Northwell Health · 2 studies
- Teachers College, Columbia University · 2 studies
- Beth Israel Medical Center
- Hackensack University Medical Center; Department of Neurology, Neuroscience Institute
What taking part in a parkinson’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting parkinson’s disease studies in New York.
Common questions
- Are there parkinson’s disease clinical trials near New York?
- Yes. We're currently tracking 35 recruiting parkinson’s disease studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a parkinson’s disease study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a parkinson’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New parkinson’s disease studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.